Matthew Henderson, DO
An underlying autoimmune condition may have played a role in making a 13-year-old patient refractory to treatment for immune thrombocytopenia (ITP) according to findings from a case study presented at the 2018 American Society of Pediatric Hematology/Oncology Conference.1
“There’s a lot of literature looking at children with lupus or scleroderma who develop ITP and how to manage those patients,” he added. “Looking at dermatomyositis as another condition and relating that to the ITP field is important.”
- Wright E, Henderson M, Patton D, Savelli S. Management of bleeding in a patient with juvenile dermatomyositis and unresponsive immune thrombocytopenia. Presented at: the 2018 ASPHO Conference; May 2-5, 2018; Pittsburgh, PA. Poster 106.
- Rijcken E, Mees ST, Bispin G, et al. Laparoscopic splenectomy for medically refractory immune thrombocytopenia (ITP): a retrospective cohort study on longtime response predicting factors based on consensus criteria. Int J Surg. 2014; 12(12):1428-33. doi: 10.1016/j.ijsu.2014.10.012.
- Lovenox [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2017. http://products.sanofi.us/lovenox/lovenox.html#Boxed%20Warning. Accessed May 14, 2018.
... to read the full story